Germany's Merck in fresh bid to enter U.S. MS pill market

FRANKFURT (Reuters) - Germany's Merck KGaA is reviving plans to bring an oral multiple sclerosis (MS) treatment to the U.S. market, hoping for blockbuster sales despite regulatory concerns about side effects having frustrated its ambitions almost seven years ago.